The p63 by IHC (Immunohistochemistry) test is a diagnostic procedure used to detect the p63 protein in tissue samples. p63 is a nuclear transcription factor expressed in squamous epithelial cells and certain tumors. This test is performed to help pathologists identify squamous cell carcinomas, distinguish them from other malignancies, and confirm tumor origin. It is particularly useful in evaluating lung, head and neck, and urothelial cancers, guiding accurate diagnosis and supporting effective treatment planning.
Yes, p63 positivity strongly supports squamous cell carcinoma, while adenocarcinomas are usually negative, helping pathologists differentiate between these tumor types.
Certainly, p63 is commonly expressed in lung squamous cell carcinoma, aiding in distinguishing it from lung adenocarcinoma which is typically p63 negative.
Yes, p63 positivity is often seen in urothelial carcinomas, supporting diagnosis and tumor classification.
No, p63 is used alongside other markers such as CK5/6, CK7, and TTF-1 to ensure accurate tumor identification.
Adenocarcinomas of the lung, colon, and breast are usually p63 negative, helping distinguish them from squamous tumors.
Expression is generally consistent across squamous carcinomas, but intensity may vary with tumor differentiation.
Yes, p63 positivity supports diagnosis of squamous cell carcinoma in head and neck tumors.
Yes, p63 is expressed in basal cells of benign prostate tissue but absent in most prostate adenocarcinomas, aiding differentiation.
...
Didn't recieved OTP Yet? Resend OTP